Cargando...

The value of imaging and clinical outcomes in a phase II clinical trial of a lysophosphatidic acid receptor antagonist in idiopathic pulmonary fibrosis

BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive fibrotic lung disease characterized by worsening dyspnea and lung function and has a median survival of 2–3 years. Forced vital capacity (FVC) is the primary endpoint used most commonly in IPF clinical trials as it is the best...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Ther Adv Respir Dis
Main Authors: Kim, Grace Hyun J., Goldin, Jonathan G., Hayes, Wendy, Oh, Andrea, Soule, Benjamin, Du, Shuyan
Formato: Artigo
Idioma:Inglês
Publicado: SAGE Publications 2021
Assuntos:
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC8013716/
https://ncbi.nlm.nih.gov/pubmed/33781141
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/17534666211004238
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!